Pauwels, Elin
Cleeren, Frederik
Tshibangu, Térence
Koole, Michel
Serdons, Kim
Dekervel, Jeroen
Van Cutsem, Eric
Verslype, Chris
Van Laere, Koen
Bormans, Guy
Deroose, Christophe M. http://orcid.org/0000-0002-6080-1577
Funding for this research was provided by:
Kom op tegen Kanker
Fonds Wetenschappelijk Onderzoek (12R3119N, G0D8817N)
Article History
Received: 9 April 2020
Accepted: 7 June 2020
First Online: 2 July 2020
Compliance with ethical standards
:
: Eric Van Cutsem has received research grants and personal fees for consultancy from Amgen, Bayer, Boehringer Ingelheim, Celgene, Ipsen, Lilly, Roche, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche and Servier. Chris Verslype has received research grants and performed consultancy services for Novartis and Ipsen. Koen Van Laere has performed consultancy services and contract research through KU Leuven for GE Healthcare, Merck, Janssen Pharmaceuticals, UCB, Syndesi Therapeutics, Curasen, Celgene and Eikonizo. Guy Bormans has performed funded contract research through KU Leuven with Eikonizo, Merck, Celgene, Janssen Pharmaceuticals, Lundbeck and UCB. Christophe M. Deroose has been a consultant through KU Leuven for Novartis, Terumo, AAA, Ipsen, Sirtex, Bayer outside the scope of the submitted work. There are no other conflicts of interest.
: All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Ethische Commissie Onderzoek UZ/KU Leuven S61727) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Written informed consent was obtained from all individual participants included in the study.